On February 18, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential opinion in an appeal by Canfield Scientific, Inc. (Canfield) from the decision of the U.S. Patent Trial and Appeal Board (PTAB or Board) on inter partes review (IPR) of U.S. Patent No. 7,359,748 (the ‘748 patent) owned by Melanoscan, LLC. The court held that the Board erred in ruling that all the claims of the ‘748 patent were patentable. The decision was reversed with respect to the independent claims and vacated and remanded as to the dependent claims.
CAFC Reverses In-Part, Vacates In-Part PTAB Finding of Patentability for Skin Cancer Detection Device
No Comments
Litigation
- The New Copyright Small Claims Board Presents Problems for Copyright Owners and Small Businesses
- Dyk Splits from CAFC Panel on Application of Collateral Estoppel to Inter Partes Reexaminations
- CAFC Reverses In-Part, Vacates In-Part PTAB Finding of Patentability for Skin Cancer Detection Device
- UK Judge Backs Meghan Markle over Leaked Letter
- Federal Circuit Says Amgen’s Repatha® Patent Claims Require ‘Undue Experimentation’ to Practice
Recent Posts
- Balancing Innovation and Competition: Thomas Jefferson’s View of Obviousness for Mechanical Inventions
- Design Patents: Under Utilized and Overlooked
- Deciding Where to Obtain International Patent Rights
- The New Copyright Small Claims Board Presents Problems for Copyright Owners and Small Businesses
- From Home Security to VoIP: Honoring Black Women Inventors of the Last Half-Century